



Healthy, Clear Nails Made Simple

A non-thermal, FDA-cleared laser for the temporary increase of clear nail in patients with onychomycosis.

A clinically validated solution designed to deliver consistent outcomes without pain, downtime, or compromise.

RETHINKING ONYCHOMYCOSIS TREATMENT

Onychomycosis affects a significant portion of the patient population and remains one of the most challenging conditions to treat effectively. Traditional therapies often fail to balance efficacy, safety, and patient compliance.

LIMITATIONS OF CONVENTIONAL TREATMENTS



ORAL ANTIFUNGALS

May present systemic risks and require monitoring.



TOPICAL THERAPIES

Often struggle with nail penetration and adherence.



THERMAL LASERS

Rely on heat, which can cause discomfort and inconsistent patient experiences.

Clinicians need a solution that prioritizes **both outcomes and patient experience.**

A NON-THERMAL, CLINICALLY PROVEN SOLUTION

Lunula® utilizes dual-wavelength low-level laser technology to deliver non-thermal photonic energy to the treatment area. This approach supports the natural processes involved in clear nail growth—without heat, tissue damage, or patient discomfort.

- ✓ NO PAIN, NO DOWNTIME, NO RISK
- ✓ 6.1 MM AVERAGE NEW CLEAR NAIL GROWTH AT 6 MONTHS
- ✓ NO DANGEROUS SMOKE PLUMES
- ✓ FDA MARKET CLEARED

“ Our practice purchased the Lunula Laser approximately one year ago. We were initially unsure of our investment. Over time, we have used the laser extensively with excellent results.


We operate multiple offices, and transportation of the laser is quite easy. We are very pleased with our investment.

The laser has also brought in many new patients seeking treatment, while providing an effective adjunct for our existing patients. ”

-Podiatric Practice



CLINICAL RESULTS



Clinical Study Overview

Published in Journal of Clinical and Aesthetic Dermatology 2017;10(5):24–30.



89%

of treated toenails showed an increase in clear nail



6.18 mm

average new clear nail growth



67%

achieved ≥ 3 mm clear nail growth (treatment success)



No adverse events were reported during the study period.

¹ Data derived from three independent clinical trials utilizing a dual-wavelength (405 nm and 635 nm) non-thermal laser device (LunulaLaser®, Erchonia Corporation).

Non-thermal laser therapy demonstrated a safe and effective approach for increasing clear nail in patients with onychomycosis following a short treatment protocol.

METHODS

This retrospective analysis included toenails from three independent clinical trials. Each trial followed comparable protocols and inclusion criteria. Subjects received weekly non-thermal laser treatments for 4 weeks (Studies 1 & 3) or 2 weeks (Study 2). Evaluations were conducted up to 6 months.

PATIENT PROFILE

- Total subjects across studies: 382
- Mean age range: ~44–59 years
- Mean infection duration: up to 8+ years
- Nail involvement: up to 100% of nail surface

RESULTS

- Significant increase in clear nail observed across all studies ($p < 0.0001$)
- Mean clear nail length increased from 7.64 mm at baseline to 12.82 mm at 6 months
- Up to 96% success rate (≥ 3 mm clear nail growth) in one study cohort

SUMMARY OF CLINICAL STUDIES

STUDY	SUBJECTS	PROTOCOL	OUTCOME
Study 1	168	Weekly for 4 weeks Follow-up to 6 months	Mean clear nail increased from 4.6 mm to 9.6 mm 62% achieved success (≥ 3 mm clear nail growth)
Study 2	105	Weekly for 2 weeks Follow-up to 6 months	Mean clear nail increased to 15.1 mm 96% achieved success
Study 3	109	Weekly for 4 weeks Follow-up to 6 months	Significant improvement observed ($p < 0.0001$). Mean affected nail decreased to 31.3%

Defining Laser Precision for 30 Years

For 30 years, Erchonia has defined and advanced the field of low-level laser therapy—establishing a category grounded in scientific rigor, safety, and clinical integrity.

Through a relentless focus on precision and innovation, Erchonia has developed non-thermal laser technologies that elevate the standard of care without compromise.

22 FDA MARKET CLEARANCES

Backed by 22 FDA market clearances and decades of clinical research, Erchonia continues to lead the industry—delivering refined, effective solutions trusted by medical professionals worldwide.



30 YEARS OF LEADERSHIP



SCIENCE DRIVEN



SAFETY FOCUSED



TRUSTED WORLDWIDE